• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the Week of April 2

Article

The Center for Biosimilars® recaps the top 5 biosimilars articles for the week of April 2, 2018.

Transcript:

Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of April 2.

Number 5: A recently published descriptive review finds a significant time lag between the approval of biosimilar infliximab and its acceptance in Irish hospitals.

Number 4: The Senate Homeland Security and Government Affairs Committee has released a report on prescription drug price increases that affect drugs that seniors use most. According to the report, drug prices rise at approximately 10 times the rate of inflation.

Number 3: CMS will lower the maximum co-payment amount for low-income subsidy beneficiaries for biosimilars.

Number 2: Samsung Bioepis and Biogen have reached a settlement with AbbVie that will allow the biosimilar adalimumab, Imraldi, to launch in Europe later this year.

Number 1: Celltrion has announced that the FDA has issued Complete Response Letters for 2 of its proposed biosimilar products.

Also this week, expert contributor Sonia T. Oskouei explains 9 key facts about biosimilar interchangeability in the United States.

Finally, last week, our e-newsletter asked whether you think one payer’s recent decision not to undertake a nonmedical switch to a biosimilar is good news for patients.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Newsletter

Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.

Recent Videos
Canavan & O’Dell
Elie Bahou, MD, PhD
Steve Pickette, PharmD
© 2025 MJH Life Sciences

All rights reserved.